Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05072314 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial

Study acronym: LOLIPOP
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 9 months later Jul 2027 → May 2028
See other at-risk trials from Monash University

Record History

  1. Primary completion pushed from Jul 2027 to May 2028 Completion pushed from Jul 2028 to May 2029 · Study sites: 47 to 49v19 Show 2 more changesShow less
    • Completion pushed from Jul 2028 to May 2029
    • Study sites: 47 to 49
  2. Study sites: 45 to 47v18
  3. Study sites: 43 to 45v17
  4. Study sites: 39 to 43v16
  5. Study sites: 37 to 39 Eligibility criteria expanded, about 32 words · Secondary endpoints: 20 to 18v15 Show 2 more changesShow less
    • Eligibility criteria expanded, about 32 words
    • Secondary endpoints: 20 to 18

    See this version in full on ClinicalTrials.gov ↗

Show 13 earlier versionsHide 13 earlier versions
  1. Study sites: 39 to 37v14
  2. Study sites revised (39)v13 See this version in full on ClinicalTrials.gov ↗
  3. Study sites: 38 to 39v12
  4. Study sites: 37 to 38v11
  5. Site details revised at 1 of 37 sitesv10
  6. Phase: Phase 4 to Phase 3 Eligibility criteria revised · Site details revised at 2 of 37 sitesv9 Show 2 more changesShow less
    • Eligibility criteria revised
    • Site details revised at 2 of 37 sites

    See this version in full on ClinicalTrials.gov ↗

  7. Primary endpoint revised Study sites: 30 to 37 · Eligibility criteria expanded, about 10 words · Secondary endpoints: 15 to 20v8 Show 3 more changesShow less
    • Study sites: 30 to 37
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: 15 to 20

    See this version in full on ClinicalTrials.gov ↗

  8. Study sites: 28 to 30 Eligibility criteria shortened, about 10 words · Secondary endpoints: 14 to 15 · Publications: 1 to 2v7 Show 3 more changesShow less
    • Eligibility criteria shortened, about 10 words
    • Secondary endpoints: 14 to 15
    • Publications: 1 to 2

    See this version in full on ClinicalTrials.gov ↗

  9. Study sites: 29 to 28 Secondary endpoints: details revised at 5 of 14 entries · Eligibility criteria shortened, about 3 wordsv6 Show 2 more changesShow less
    • Secondary endpoints: details revised at 5 of 14 entries
    • Eligibility criteria shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  10. Study sites: 28 to 29 Primary completion date: Feb 2027 to Jul 2027 · Completion date: Feb 2028 to Jul 2028v5 Show 2 more changesShow less
    • Primary completion date: Feb 2027 to Jul 2027
    • Completion date: Feb 2028 to Jul 2028
  11. Study sites: 1 to 28v4
  12. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Jul 2022 to Jul 27, 2022 · Eligibility criteria expanded, about 2 wordsv3 Show 3 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Jul 2022 to Jul 27, 2022
    • Eligibility criteria expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  13. Start date: Feb 2022 to Jul 2022 Eligibility criteria expanded, about 22 words · Study description shortened, about 29 wordsv2 Show 2 more changesShow less
    • Eligibility criteria expanded, about 22 words
    • Study description shortened, about 29 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Monash University
29 trials monitored
See 3 trials at risk
Breast Cancer
5,213 trials monitored
See 271 trials at risk
The LOLIPOP Trial is a large (n=4,300 patients) pragmatic, international, multicentre, prospective, randomised, double blind, placebo-controlled, parallel assessment, safety and effectiveness superiority study.
Trial Details
NCT Number NCT05072314
Lead Sponsor Monash University
Collaborators: Royal Perth Hospital
Conditions Breast Cancer, Breast Cancer Female, Breast Conserving Surgery, Mastectomy
Enrollment 4,300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov